Associated Pathologists Laboratories Expands its
Services to Offer Cytyc's ThinPrep(R) Pap Test(TM)
PR Newswire - January 04, 2000 11:54
BOXBOROUGH, Mass., Jan. 4 /PRNewswire/ -- Cytyc Corporation (Nasdaq: CYTC)
today announced that Associated Pathologists Laboratories (APL), based in Las Vegas,
Nevada, will offer the ThinPrep(R) Pap Test(TM) as an enhanced technology for cervical
cancer screening. APL will make the ThinPrep Pap Test available as a replacement for the
conventional Pap smear to its more than 6,000 clients.
"We have long been committed to using the best technologies to achieve accurate test results,"
said Henry B. Soloway, M.D., laboratory director for APL. "The ThinPrep Pap Test is the only
technology for cervical cancer screening that the FDA has labeled 'significantly more effective'
than the conventional Pap smear for the detection of cervical abnormalities. This, coupled with
the high volume of peer reviewed literature demonstrating improved efficacy as well as demand
for the test from our physician clients, contributed to our decision to offer the test. It's simply the
right thing to do to ensure that women have access to the best technology to screen for cervical
abnormalities."
"APL has a well deserved reputation for adopting the most effective technologies to achieve
accurate results," said Patrick J. Sullivan, Cytyc's president and chief executive officer. "We are
very pleased that they have extended this commitment to offer the ThinPrep Pap Test to meet
the expressed needs of the patients and physicians they serve."
Associated Pathologists Laboratories has provided medical laboratory and pathology services
to clients throughout the United States since 1966. APL is a subsidiary of AML/APL, Inc., a
privately held company formed by the merger of APL and American Medical Laboratories in
1999. APL is one of the largest clinical laboratories in the region, operating five full service
laboratories and offering more than 500 different diagnostic determinations. APL currently
performs 300,000 Pap tests annually and will continue to process conventional Pap smears in
addition to the ThinPrep Pap Test.
Cytyc Corporation develops, manufactures, and markets the ThinPrep(R) System for medical
diagnostic applications. The ThinPrep System consists of the ThinPrep(R) 2000 Processor and
related reagents, such as PreservCyt(R), filters, and other supplies. Since introduction of the
ThinPrep System, Cytyc has manufactured more than 1,000 ThinPrep 2000 Processors and 10
million ThinPrep(R) Pap Tests(TM) for cervical cancer screening.
Cytyc(R), PreservCyt(R), and ThinPrep(R) are registered trademarks and ThinPrep(R) Pap
Test(TM) and ThinPrep(R) Imaging System(TM) are trademarks of Cytyc Corporation.
FOR CYTYC INVESTORS:
Forward-looking statements in this press release are made pursuant to the provisions of Section
21E of the Securities Exchange Act of 1934. Investors are cautioned that statements in this
press release which are not strictly historical statements, including, without limitation, statements
regarding management's plans and objectives for future operations, product plans and
performance, potential savings to the healthcare system, management's assessment of market
factors, as well as statements regarding the strategy and plans of the Company constitute
forward-looking statements which involve risks and uncertainties, including, without limitation,
risks associated with the Company's dependence on a single product, uncertainty of market
acceptance and additional cost, dependence on timely and adequate levels of third-party
reimbursement, CPT code implementation delays and delays in reimbursement, risks associated
with potential year 2000 software disruptions involving the products and systems of the
Company and certain third party customers, suppliers, and payers, limited marketing and sales
experience, and limited number of customers and lengthy sales cycle, as well as risks of
downturns in economic conditions generally, and in the healthcare industry specifically, risks
associated with competition and competitive pricing pressures, potential liabilities and costs
associated with litigation, and other risks detailed in the Company's filings with the Securities
and Exchange Commission, including in its 1998 Form 10-K filed with the Commission.
SOURCE Cytyc Corporation
/CONTACT: Joseph Kelly, Chief Financial Officer, Anne Rivers, Investor
Relations, or Jeff Keene, Healthcare Media, all of Cytyc Corporation,
978-266-3010; or Craig Shanklin, Executive Vice President of Associated
Pathologists Laboratories, 702-733-7866/
/Web site: cytyc.com
This lab still will do that many Pap Smears? Not sure it makes sense.
Jack |
